v3.26.1
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Beginning balance $ 151,460 $ 3 $ 289,954 $ (138,396) $ (101)
Beginning balance (in shares) at Dec. 31, 2024   26,987,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of common stock options (in shares)   85,000      
Exercise of common stock options 198   198    
Issuance of K2 warrants 524   524    
Stock compensation expense 1,968   1,968    
Other comprehensive income 115       115
Net loss (15,169)     (15,169)  
Ending balance (in shares) at Mar. 31, 2025   27,072,000      
Ending balance at Mar. 31, 2025 139,096 $ 3 292,644 (153,565) 14
Beginning balance (in shares) at Dec. 31, 2024   26,987,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Other comprehensive income 132        
Net loss (32,875)        
Ending balance (in shares) at Jun. 30, 2025   27,072,000      
Ending balance at Jun. 30, 2025 123,412 $ 3 294,649 (171,271) 31
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Beginning balance 139,096 $ 3 292,644 (153,565) 14
Beginning balance (in shares) at Mar. 31, 2025   27,072,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock compensation expense 2,005   2,005    
Other comprehensive income 17       17
Net loss (17,706)     (17,706)  
Ending balance (in shares) at Jun. 30, 2025   27,072,000      
Ending balance at Jun. 30, 2025 123,412 $ 3 294,649 (171,271) 31
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Beginning balance 123,412 3 294,649 (171,271) 31
Beginning balance $ 151,142 $ 3 352,751 (201,634) 22
Beginning balance (in shares) at Dec. 31, 2025 31,923,521 31,924,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of common stock options (in shares)   4,000      
Exercise of common stock options $ 6   6    
Restricted stock units vesting (in shares)   18,000      
Restricted stock units vesting (190)   (190)    
Issuance of common stock and pre-funded warrants in 2026 private placement, net of issuance costs (in shares)   2,900,000      
Issuance of common stock and pre-funded warrants in 2026 private placement, net of issuance costs 114,892   114,892    
Issuance of common stock for conversion of the K2 term loan, net of issuance (in shares)   207,000      
Issuance of common stock for conversion of the K2 term loan, net of issuance 941   941    
Stock compensation expense 2,824   2,824    
Other comprehensive income (9)       (9)
Net loss (26,237)     (26,237)  
Ending balance (in shares) at Mar. 31, 2026   35,053,000      
Ending balance at Mar. 31, 2026 $ 243,369 $ 3 471,224 (227,871) 13
Beginning balance (in shares) at Dec. 31, 2025 31,923,521 31,924,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Other comprehensive income $ (5)        
Net loss $ (53,875)        
Ending balance (in shares) at Jun. 30, 2026 35,093,940 35,094,000      
Ending balance at Jun. 30, 2026 $ 219,249 $ 3 474,738 (255,509) 17
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Beginning balance 243,369 $ 3 471,224 (227,871) 13
Beginning balance (in shares) at Mar. 31, 2026   35,053,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of common stock options (in shares)   41,000      
Exercise of common stock options 75   75    
Stock compensation expense 3,554   3,554    
Issuance costs related to the 2026 private placement (115)   (115)    
Other comprehensive income 4       4
Net loss $ (27,638)     (27,638)  
Ending balance (in shares) at Jun. 30, 2026 35,093,940 35,094,000      
Ending balance at Jun. 30, 2026 $ 219,249 $ 3 474,738 (255,509) 17
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Beginning balance $ 219,249 $ 3 $ 474,738 $ (255,509) $ 17